Format

Send to

Choose Destination
Curr Opin Immunol. 2005 Apr;17(2):195-201.

Less is more: lymphodepletion followed by hematopoietic stem cell transplant augments adoptive T-cell-based anti-tumor immunotherapy.

Author information

1
National Cancer Institute, National Institutes of health, Clinical Research Center, Room 3-5816, 10 Center Drive, Bethesda, MD 20892-1201, USA. wrzesinc@mail.nih.gov

Abstract

Adoptive T-cell immunotherapy combined with non-myeloablative lymphodepletion has emerged as the most effective immunotherapy treatment for patients with metastatic melanoma (objective response rates of 50%). The mechanisms underlying this major advance in the field of immunotherapy include the elimination of regulatory elements and increased access to activating cytokines. This results in the activation of low-affinity T cells, enabling them to destroy tumors. We propose that a more complete depletion of the patient's immune system followed by transplantation with hematopoietic stem cells, which can be genetically modified, would be more effective in the treatment of metastatic cancer.

PMID:
15766681
PMCID:
PMC2254579
DOI:
10.1016/j.coi.2005.02.002
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Elsevier Science Icon for PubMed Central
Loading ...
Support Center